title: Lymphokine-activated killer cells induced from decidual lymphocytes reduce the angiogenic activity of trophoblasts by enhancing the release of soluble fms-like tyrosine kinase-1 from trophoblasts: an implication for the pathophysiology of preeclampsia.
abstract: T helper (Th)1 cytokine-predominating status and compromised placental vasculature is thought to be central to the pathogenesis of preeclampsia. However, it remains to be clarified how these two phenomena relate to each other. We have reported that lymphokine-activated killer (LAK) cells induced from decidual mononuclear cells (DMCs) with interleukin (IL)-2 expressed in preeclamptic placenta reduced the angiogenic activity of cytotrophoblasts (CTs). The objective of this study was to examine how LAK cells reduced the angiogenic activity of CTs. We investigated the angiogenesis-related molecules released from cultured CTs obtained from first trimester placenta that had been pretreated with either non-activated DMCs or LAK cells from DMCs. The amounts of vascular endothelial growth factor (VEGF), placenta growth factor (PlGF) and their antagonist, soluble fms-like tyrosine-kinase-1 (sFlt-1) released in CT culture media were measured using ELISA. CTs pretreated with LAK cells released more sFlt-1 compared with those pretreated with non-activated lymphocytes, and CTs pretreated with non-activated lymphocytes released more sFlt-1 compared with those without pretreatment. The release of total VEGF and free PlGF from CTs was not altered by pretreatment with DMCs. Thus, in preeclamptic placenta, LAK cells induced from DMCs by co-existing IL-2 may react to the invading CTs and enhance the release of sFlt-1 from CTs without any change of VEGF or PlGF secretion. This might result in the reduction of actual angiogenic potential of the VEGF system in decidua and the placental vascular system might be compromised, which may lead to the development of preeclampsia.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Tokyo, 113-8655 Japan.
authors.forename: Kaya
authors.initials: K
authors.lastname: Matsubara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nagamatsu
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Fujii
authors.forename: Shiro
authors.initials: S
authors.lastname: Kozuma
authors.forename: Yuji
authors.initials: Y
authors.lastname: Taketani
mesh_terms: D002478:Cells, Cultured; D016207:Cytokines / Q000276:immunology; D003656:Decidua / Q000098:blood supply / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology* / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000276:immunology*; D011225:Pre-Eclampsia / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D011247:Pregnancy; D014327:Trophoblasts / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000276:immunology* / Q000378:metabolism
chemical_list: D016207:Cytokines; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1